<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566878</url>
  </required_header>
  <id_info>
    <org_study_id>AGLU03406</org_study_id>
    <secondary_id>LTS13972</secondary_id>
    <nct_id>NCT00566878</nct_id>
  </id_info>
  <brief_title>Pompe Lactation Sub-Registry</brief_title>
  <official_title>A Sub-Registry to Determine the Presence of Alglucosidase Alfa in Breast Milk From Women With Pompe Disease Treated With Alglucosidase Alfa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine if alglucosidase alfa is present in breast milk from mothers
      with Pompe Disease being treated with alglucosidase alfa and to measure breast milk
      production and composition in women with Pompe Disease who receive alglucosidase alfa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>alglucosidase alfa accumulation in immature (1-3 months post partum) or mature (4-6 months post partum) breast milk sample from mothers with Pompe disease who are being treated with alglucosidase alfa.</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>breast milk production and composition in women with Pompe disease who receive alglucosidase alfa</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Glycogen Storage Disease</condition>
  <condition>Pompe Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alglucosidase alfa</intervention_name>
    <description>At least one infusion of alglucosidase alfa post partum</description>
    <other_name>Myozyme</other_name>
    <other_name>Lumizyme</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Females diagnosed with Pompe Disease and Lactating
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be enrolled in Pompe Registry (NCT00231400)

          -  Must be pregnant and intend to breast-feed or be currently lactating and receive at
             least one infusion of alglucosidase alfa while lactating

          -  Provide a signed Patient Information and Authorization form to participate in the
             sub-registry prior to any sub-registry-related assessments are performed

          -  Agree to adhere to the sub-registry guidelines for antibody testing and recommended
             schedule of assessments.

        Exclusion Criteria:

          -  Patients will be excluded from this sub-registry if they have received an
             investigational drug (excluding alglucosidase alfa in regions where alglucosidase alfa
             is not commercially available) within 30 days prior to Visit 1 breast milk collection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>800-745-4447</phone>
    <email>MedInfo@genzyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>617-252-7832</phone>
    <email>MedInfo@genzyme.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Registry participation is worldwide. Facilities not yet active may enroll upon identification of a patient</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2007</study_first_submitted>
  <study_first_submitted_qc>December 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycogen Storage Disease</keyword>
  <keyword>GSD-II</keyword>
  <keyword>Pompe Disease</keyword>
  <keyword>Pompe Disease (Late-Onset)</keyword>
  <keyword>Acid Maltase Deficiency Disease</keyword>
  <keyword>Glycogenosis II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

